{
  "event": {
    "ticker": "SMMT",
    "company": "Summit Therapeutics Inc.",
    "drug": "ivonescimab (AK112)",
    "application_type": "BLA",
    "indication": "Ivonescimab + platinum-doublet chemotherapy, EGFR-mutated locally advanced or metastatic non-squamous NSCLC after a third-generation EGFR TKI (HARMONi)",
    "pdufa_date": "2026-11-14"
  },
  "display": {
    "company": "Summit",
    "drug": "ivonescimab",
    "indication_en": "EGFR-mutated lung cancer",
    "indication_zh": "EGFR 突变肺癌"
  },
  "probability_approval": 0.45,
  "confidence": "low",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "FDA's stated approval bar was not met in the prespecified analysis",
      "direction": "-",
      "step": "large",
      "evidence": "Summit's 10-K says the FDA noted that a statistically significant overall survival benefit is necessary to support marketing authorization in this setting. HARMONi's primary OS analysis missed it: HR 0.79 (95% CI 0.62–1.01), p=0.057.",
      "source": "SEC 10-K filed 2026-02-23; 8-K 2026-07-22"
    },
    {
      "factor": "The totality of evidence is supportive: strong PFS, an OS trend that holds with longer follow-up, and a positive OS readout in the China-only study",
      "direction": "+",
      "step": "medium",
      "evidence": "PFS was statistically significant (primary endpoint). An updated June-2026 OS cut gives HR 0.76 in the ITT population and in western patients, but it is descriptive and does not restore the alpha spent. HARMONi-A (China) showed significant OS with HR 0.74. The FDA has historically discounted single-country China data.",
      "source": "SEC 8-K 2026-07-22, 8-K 2026-09-15 (WCLC 2026), 10-K 2026-02-23"
    },
    {
      "factor": "The FDA accepted the BLA for filing despite the known OS miss",
      "direction": "+",
      "step": "small",
      "evidence": "The BLA was submitted Q4 2025 and accepted January 2026, with no refuse-to-file. Acceptance means the file is complete, not that it is approvable.",
      "source": "SEC 8-K 2026-09-15; OncLive / CancerNetwork BLA acceptance coverage"
    },
    {
      "factor": "A PFS-based precedent exists in the same post-osimertinib setting",
      "direction": "+",
      "step": "small",
      "evidence": "Amivantamab + carboplatin/pemetrexed (MARIPOSA-2) was approved on PFS without mature OS. The FDA's drug-specific statement to Summit outweighs the general precedent. PD-1 agents have failed to show OS benefit in EGFRm NSCLC, which likely explains the FDA's higher bar.",
      "source": "FDA approval coverage of MARIPOSA-2 (CancerNetwork, PMC11981408)"
    },
    {
      "factor": "Manufacturing in China and a pre-license inspection",
      "direction": "-",
      "step": "small",
      "evidence": "Drug supply comes from partner Akeso in China. A pre-license inspection of the Chinese site is required. Summit's risk factors flag US–China trade risk and the BIOSECURE Act, signed December 2025. Other Chinese PD-1 antibodies (toripalimab, tislelizumab, penpulimab) were eventually approved; toripalimab's first cycle ended in a CRL that was partly inspection-related.",
      "source": "SEC 10-K 2026-02-23 risk factors"
    },
    {
      "factor": "Standard review and no advisory committee announced about six weeks before the PDUFA date",
      "direction": "-",
      "step": "small",
      "evidence": "An efficacy question this contested is often taken to ODAC. Deciding without one can cut either way; the lack of a priority review is mildly negative.",
      "source": "No ODAC listing found in public sources as of 2026-10-04"
    }
  ],
  "manufacturing_risk": {
    "level": "medium",
    "why": "Biologic made by a Chinese partner, so a foreign pre-license inspection is needed, with policy risk from the BIOSECURE Act. Chinese PD-1 makers have since passed FDA inspections, so this is a secondary risk next to the efficacy question."
  },
  "what_would_change_my_mind": [
    "The FDA schedules ODAC, or the company discloses late-cycle meeting outcomes or label negotiations",
    "A statistically significant result from a prespecified updated OS analysis, or the FDA publicly accepting the updated OS data",
    "A PDUFA extension (major amendment) would not change the forecast by itself, only its date",
    "News of an inspection problem, or an import or BIOSECURE designation affecting Akeso"
  ],
  "summary_en": "We put approval in this review cycle at 45%, below the ~76% base rate for small/mid-cap original applications. The dominant factor is that the FDA told Summit a statistically significant overall-survival benefit is necessary in this setting, and HARMONi's prespecified OS analysis missed (HR 0.79, p=0.057). Against that: a clearly positive PFS result, a consistent OS trend with longer follow-up (HR 0.76, descriptive), significant OS in the China-only HARMONi-A study, and a PFS-based precedent in the same setting. Manufacturing in China adds secondary inspection risk. Confidence is low: this is a judgment call the FDA could make either way.",
  "summary_zh": "我们估计本轮审评获批概率为 45%，低于中小型公司新药约 76% 的基准。最关键的是 FDA 曾明确表示，该适应症需要统计显著的总生存期获益，而 HARMONi 预设的总生存期分析未达标（HR 0.79，p=0.057）。支持获批的因素包括：无进展生存期显著获益，延长随访后总生存期趋势一致（HR 0.76，描述性），中国单区域 HARMONi-A 研究总生存期显著，以及同一适应症有仅凭无进展生存期获批的先例。药物在中国生产，需接受 FDA 现场检查，构成次要风险。本次判断把握度低，FDA 两种决定都有可能。",
  "sources": [
    "SEC 10-K, Summit Therapeutics, filed 2026-02-23 (FDA statement on OS requirement; China/BIOSECURE risk factors)",
    "https://www.sec.gov/Archives/edgar/data/1599298/ — 8-K 2026-07-22 (updated HARMONi OS analysis, HR 0.76)",
    "SEC 8-K 2026-09-15 (WCLC 2026 updated HARMONi data; BLA accepted January 2026; PDUFA 2026-11-14)",
    "https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/a2026_prx0506xq12026earn.htm",
    "https://www.onclive.com/view/fda-receives-bla-for-ivonescimab-plus-chemo-in-second-line-or-later-egfr-mutant-nsclc",
    "https://www.fiercepharma.com/pharma/summit-therapeutics-updates-ivonescimab-survival-data-ahead-fda-decision-date",
    "https://www.cancernetwork.com/view/fda-approves-amivantamab-combo-in-advanced-egfr-nsclc",
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981408/"
  ],
  "zh": {
    "indication": "Ivonescimab 联合含铂双药化疗，用于第三代 EGFR TKI 治疗后的 EGFR 突变局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）；HARMONi 研究",
    "key_factors": [
      {
        "factor": "预设分析未达到 FDA 明确提出的获批门槛",
        "evidence": "Summit 的 10-K 显示，FDA 指出在该治疗背景下，需要统计学显著的总生存期（OS）获益才能支持上市许可。HARMONi 的主要 OS 分析未达到这一标准：风险比（HR）0.79（95% CI 0.62–1.01），p=0.057。"
      },
      {
        "factor": "整体证据具有支持性：无进展生存期（PFS）获益明确，OS 趋势在更长随访中保持，且仅在中国开展的研究 OS 结果为阳性",
        "evidence": "PFS（主要终点）达到统计学显著。2026 年 6 月更新的 OS 数据截点显示，ITT 人群和西方患者的 HR 均为 0.76，但该分析为描述性分析，无法弥补已消耗的 α。HARMONi-A（中国）显示 OS 显著获益，HR 为 0.74。FDA 历来对仅来自中国单一国家的数据持保留态度。"
      },
      {
        "factor": "尽管 OS 未达标已为人所知，FDA 仍受理了该生物制品许可申请（BLA）",
        "evidence": "BLA 于 2025 年第四季度提交，2026 年 1 月获受理，未被拒绝受理。受理仅意味着申报资料完整，并不代表可以获批。"
      },
      {
        "factor": "在同一 osimertinib 治疗后人群中，已有基于 PFS 获批的先例",
        "evidence": "Amivantamab 联合 carboplatin/pemetrexed（MARIPOSA-2）在 OS 数据尚未成熟时即基于 PFS 获批。不过，FDA 针对本药向 Summit 作出的具体表态比一般性先例更有分量。PD-1 类药物在 EGFR 突变 NSCLC 中未能证明 OS 获益，这很可能是 FDA 提高门槛的原因。"
      },
      {
        "factor": "在中国生产，需进行批准前检查",
        "evidence": "药品由合作方 Akeso 在中国供应，中国生产场地须接受批准前检查。Summit 的风险因素提示了中美贸易风险，以及 2025 年 12 月签署生效的 BIOSECURE 法案。其他中国 PD-1 抗体（toripalimab、tislelizumab、penpulimab）最终均获批准；toripalimab 首轮审评以完全回应函（CRL）告终，部分原因与检查相关。"
      },
      {
        "factor": "适用标准审评，且距 PDUFA 目标日期约六周仍未宣布召开专家咨询委员会会议",
        "evidence": "争议如此大的疗效问题通常会提交肿瘤药物咨询委员会（ODAC）讨论。不召开会议直接作出决定，可能指向任一方向；未获优先审评则略偏负面。"
      }
    ],
    "manufacturing_risk_why": "该生物制品由中国合作方生产，因此需要进行境外批准前检查，并面临 BIOSECURE 法案带来的政策风险。此后已有中国 PD-1 生产商通过 FDA 检查，因此相较于疗效问题，这属于次要风险。",
    "what_would_change_my_mind": [
      "FDA 安排 ODAC 会议，或公司披露后期审评会议结果或说明书谈判情况",
      "预设的 OS 更新分析取得统计学显著结果，或 FDA 公开接受更新后的 OS 数据",
      "PDUFA 目标日期延期（重大修改）本身不会改变预测，只会改变日期",
      "出现检查问题，或针对 Akeso 的进口限制或 BIOSECURE 认定的消息"
    ]
  },
  "recorded_at": "2026-10-04T19:58:08+00:00"
}